Stem definition | Drug id | CAS RN |
---|---|---|
halogenated compounds used as general inhalation anaesthetics | 1493 | 26675-46-7 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 18, 1979 | FDA | BAXTER HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Propofol infusion syndrome | 126.51 | 57.83 | 23 | 2058 | 758 | 46683223 |
Mitochondrial DNULL mutation | 122.41 | 57.83 | 19 | 2062 | 232 | 46683749 |
Intra-abdominal pressure increased | 109.86 | 57.83 | 17 | 2064 | 203 | 46683778 |
Pneumatosis | 105.31 | 57.83 | 18 | 2063 | 412 | 46683569 |
Gene mutation | 94.72 | 57.83 | 19 | 2062 | 1061 | 46682920 |
Intestinal ischaemia | 94.21 | 57.83 | 27 | 2054 | 6898 | 46677083 |
Apnoea | 92.66 | 57.83 | 27 | 2054 | 7312 | 46676669 |
Status epilepticus | 90.96 | 57.83 | 31 | 2050 | 13948 | 46670033 |
Hyperthermia malignant | 89.06 | 57.83 | 17 | 2064 | 732 | 46683249 |
Necrosis ischaemic | 87.02 | 57.83 | 17 | 2064 | 828 | 46683153 |
Blood gases abnormal | 85.41 | 57.83 | 16 | 2065 | 622 | 46683359 |
Exposure during pregnancy | 81.85 | 57.83 | 54 | 2027 | 108158 | 46575823 |
Delayed recovery from anaesthesia | 74.62 | 57.83 | 15 | 2066 | 846 | 46683135 |
Systemic inflammatory response syndrome | 68.84 | 57.83 | 20 | 2061 | 5351 | 46678630 |
Post procedural complication | 68.80 | 57.83 | 26 | 2055 | 15703 | 46668278 |
Metabolic acidosis | 63.34 | 57.83 | 32 | 2049 | 38748 | 46645233 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthermia malignant | 220.62 | 51.89 | 45 | 1991 | 1789 | 29948653 |
Apnoea | 111.28 | 51.89 | 33 | 2003 | 6225 | 29944217 |
Post procedural complication | 98.46 | 51.89 | 35 | 2001 | 11691 | 29938751 |
Hypotension | 93.03 | 51.89 | 89 | 1947 | 200476 | 29749966 |
Intestinal ischaemia | 91.29 | 51.89 | 29 | 2007 | 6868 | 29943574 |
Necrosis ischaemic | 87.55 | 51.89 | 15 | 2021 | 223 | 29950219 |
Superinfection | 79.13 | 51.89 | 19 | 2017 | 1595 | 29948847 |
Fear | 78.48 | 51.89 | 29 | 2007 | 10796 | 29939646 |
Anhedonia | 74.11 | 51.89 | 26 | 2010 | 8343 | 29942099 |
Injury | 71.23 | 51.89 | 33 | 2003 | 21698 | 29928744 |
Mucosal ulceration | 68.02 | 51.89 | 15 | 2021 | 863 | 29949579 |
Renal injury | 65.56 | 51.89 | 26 | 2010 | 11703 | 29938739 |
Systemic inflammatory response syndrome | 64.38 | 51.89 | 22 | 2014 | 6524 | 29943918 |
Emotional distress | 58.14 | 51.89 | 26 | 2010 | 15739 | 29934703 |
Source | Code | Description |
---|---|---|
ATC | N01AB06 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons |
FDA EPC | N0000175681 | General Anesthetic |
CHEBI has role | CHEBI:38870 | inhalation anesthetics |
MeSH PA | D000777 | Anesthetics |
MeSH PA | D018685 | Anesthetics, Inhalation |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
FDA PE | N0000175975 | General Anesthesia |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
General anesthesia | indication | 50697003 | |
Hyperkalemia | contraindication | 14140009 | |
Low blood pressure | contraindication | 45007003 | |
Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Malignant hyperthermia | contraindication | 405501007 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glycine receptor (alpha-1/beta) | Ion channel | POSITIVE MODULATOR | CHEMBL | CHEMBL | |||||
GABA-A receptor; anion channel | Ion channel | POSITIVE ALLOSTERIC MODULATOR | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 10 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 18 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 3 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 9 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
Potassium channel subfamily K member 2 | Ion channel | OPENER | CHEMBL | CHEMBL | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.11 | PDSP |
ID | Source |
---|---|
4019107 | VUID |
N0000147364 | NUI |
D00545 | KEGG_DRUG |
4019107 | VANDF |
C0022180 | UMLSCUI |
CHEBI:6015 | CHEBI |
ICF | PDB_CHEM_ID |
3763 | PUBCHEM_CID |
CHEMBL1256 | ChEMBL_ID |
DB00753 | DRUGBANK_ID |
D007530 | MESH_DESCRIPTOR_UI |
2505 | IUPHAR_LIGAND_ID |
3286 | INN_ID |
CYS9AKD70P | UNII |
6026 | RXNORM |
284 | MMSL |
4326 | MMSL |
4926 | MMSL |
d00267 | MMSL |
001391 | NDDF |
387368002 | SNOMEDCT_US |
66492008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
FORANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10019-360 | INHALANT | 1 mL | RESPIRATORY (INHALATION) | NDA | 22 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 12164-012 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 22 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-011 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-017 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Terrell | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-019 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 21 sections |
Isoflurane | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-020 | LIQUID | 1 mL | RESPIRATORY (INHALATION) | ANDA | 13 sections |